Ifp Advisors, Inc Regenxbio Inc. Transaction History

Ifp Advisors, Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 18, 2023	SELL	$18.08 - $24.55 $307 - $417	-17 Reduced 11.97%	125 $2,000
Q4 2022 Feb 07, 2023	SELL	$20.4 - $24.73 $1,530 - $1,854	-75 Reduced 34.56%	142 $10,000
Q3 2022 Nov 08, 2022	BUY	$22.29 - $35.04 $378 - $595	17 Added 8.5%	217 $14,000
Q2 2022 Sep 06, 2022	BUY	$19.35 - $35.04 $3,870 - $7,008	200 New	200 $11,000
Q2 2022 Aug 12, 2022	SELL	$19.35 - $35.04 $3,870 - $7,008	-200 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$21.5 - $54.2 $22,876 - $57,668	-1,064 Reduced 84.18%	200 $7,000
Q4 2019 Jan 17, 2020	BUY	$34.54 - $44.87 $36,750 - $47,741	1,064 Added 532.0%	1,264 $52,000
Q3 2019 Nov 07, 2019	BUY	$31.84 - $50.88 $1,592 - $2,544	50 Added 33.33%	200 $7,000
Q1 2019 May 15, 2019	SELL	$40.82 - $62.45 $13,266 - $20,296	-325 Reduced 68.42%	150 $9,000
Q4 2017 Jan 24, 2018	BUY	$26.0 - $34.6 $2,600 - $3,460	100 Added 26.67%	475 $0
Q3 2017 Oct 30, 2017	BUY	$18.0 - $32.95 $4,050 - $7,413	225 Added 150.0%	375 $12,000
Q1 2016 Jun 03, 2019	BUY	N/A	150	150 $9,000

193

43.5M

58.9K

58.4K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $420M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.